Long-term stability of cryopreserved human hepatocytes: Evaluation of phase I and II drug-metabolizing enzyme activities and CYP3A4/5 induction for more than a decade

Drug Metabolism and Disposition

Volumn 45, Issue 7, 2017, Pages 734-736

  Sudo, Miyako ^a   Nishihara, Mitsuhiro ^a   Takahashi, Junzo ^a   Asahi, Satoru ^a  

^a TAKEDA PHARMACEUTICAL COMPANY LIMITED   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450 1A2; CYTOCHROME P450 3A4; CYTOCHROME P450 3A5; DRUG METABOLIZING ENZYME; GLUCURONOSYLTRANSFERASE; LIQUID NITROGEN; SULFOTRANSFERASE; URIDINE DIPHOSPHATE; CYP3A4 PROTEIN, HUMAN; CYP3A5 PROTEIN, HUMAN; CYTOCHROME P450 3A;

ADULT; AGED; ARTICLE; CELL MEMBRANE; CELL VIABILITY; CONTROLLED STUDY; CRYOPRESERVATION; ENZYME ACTIVITY; ENZYME INDUCTION; FEMALE; HUMAN; HUMAN CELL; INCUBATION TIME; LIVER CELL; LIVER MICROSOME; MALE; MIDDLE AGED; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; THAWING; VERY ELDERLY; LIVER; METABOLIC CLEARANCE RATE; METABOLISM; PHYSIOLOGY; PROCEDURES; XENOBIOTIC METABOLISM;

AGED; AGED, 80 AND OVER; CRYOPRESERVATION; CYTOCHROME P-450 CYP1A2; CYTOCHROME P-450 CYP3A; ENZYME INDUCTION; FEMALE; GLUCURONOSYLTRANSFERASE; HEPATOCYTES; HUMANS; LIVER; MALE; METABOLIC CLEARANCE RATE; METABOLIC DETOXICATION, PHASE I; METABOLIC DETOXICATION, PHASE II; SULFOTRANSFERASES;

EID: 85020942826     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.117.075234     Document Type: Article

References (12)

1. Chai X, Zeng S, and Xie W (2013) Nuclear receptors PXR and CAR: implications for drug metabolism regulation, pharmacogenomics and beyond. Expert Opin Drug Metab Toxicol 9: 253–266.
2. Gonzalez FJ (1988) The molecular biology of cytochrome P450s. Pharmacol Rev 40: 243–288.
3. Hiller DL and Cole RO (1995) Short-column gradient elution high-performance liquid chromatography for the rapid determination of 7-ethoxycoumarin metabolites in liver-slice incubates. Anal Biochem 227: 251–254.
4. Krueger W, Boelsterli UA, and Rasmussen TP (2014) Stem cell strategies to evaluate idiosyncratic drug-induced liver injury. J Clin Transl Hepatol 2: 143–152.
5. Li AP, Lu C, Brent JA, Pham C, Fackett A, Ruegg CE, and Silber PM (1999) Cryopreserved human hepatocytes: characterization of drug-metabolizing enzyme activities and applications in higher throughput screening assays for hepatotoxicity, metabolic stability, and drug-drug interaction potential. Chem Biol Interact 121: 17–35.
6. Martignoni M, Groothuis GM, and de Kanter R (2006) Species differences between mouse, rat, dog, monkey and human CYP-mediated drug metabolism, inhibition and induction. Expert Opin Drug Metab Toxicol 2: 875–894.
7. McLIMANS WF, Davis EV, Glover FL, and Rake GW (1957) The submerged culture of mammalian cells; the spinner culture. J Immunol 79: 428–433.
8. Rialland L, Guyomard C, Scotte M, Chesné C, and Guillouzo A (2000) Viability and drug metabolism capacity of alginate-entrapped hepatocytes after cryopreservation. Cell Biol Toxicol 16: 105–116.
9. Sahi J, Grepper S, and Smith C (2010) Hepatocytes as a tool in drug metabolism, transport and safety evaluations in drug discovery. Curr Drug Discov Technol 7: 188–198.
10. Saito J, Okamura A, Takeuchi K, Hanioka K, Okada A, and Ohata T (2016) High content analysis assay for prediction of human hepatotoxicity in HepaRG and HepG2 cells. Toxicol In Vitro 33: 63–70.
11. Soars MG, McGinnity DF, Grime K, and Riley RJ (2007) The pivotal role of hepatocytes in drug discovery. Chem Biol Interact 168: 2–15.
12. Utesch D, Diener B, Molitor E, Oesch F, and Platt KL (1992) Characterization of cryopreserved rat liver parenchymal cells by metabolism of diagnostic substrates and activities of related enzymes. Biochem Pharmacol 44: 309–315.